- Home
- BAP vs ILMN Comparison
BAP vs ILMN Comparison
Compare BAP & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAP
- ILMN
- Stock Information
- Founded
- BAP 1889
- ILMN 1998
- Country
- BAP Peru
- ILMN United States
- Employees
- BAP N/A
- ILMN N/A
- Industry
- BAP Major Banks
- ILMN Medical Specialities
- Sector
- BAP Finance
- ILMN Health Care
- Exchange
- BAP Nasdaq
- ILMN Nasdaq
- Market Cap
- BAP 21.1B
- ILMN 15.3B
- IPO Year
- BAP 1995
- ILMN 2000
- Fundamental
- Price
- BAP $259.01
- ILMN $121.18
- Analyst Decision
- BAP Buy
- ILMN Hold
- Analyst Count
- BAP 6
- ILMN 15
- Target Price
- BAP $245.00
- ILMN $114.93
- AVG Volume (30 Days)
- BAP 242.5K
- ILMN 2.1M
- Earning Date
- BAP 11-13-2025
- ILMN 10-30-2025
- Dividend Yield
- BAP 4.25%
- ILMN N/A
- EPS Growth
- BAP 26.90
- ILMN N/A
- EPS
- BAP 22.19
- ILMN 4.46
- Revenue
- BAP $5,576,317,301.00
- ILMN $4,288,000,000.00
- Revenue This Year
- BAP $24.87
- ILMN N/A
- Revenue Next Year
- BAP $7.51
- ILMN $2.22
- P/E Ratio
- BAP $11.67
- ILMN $27.33
- Revenue Growth
- BAP 20.05
- ILMN N/A
- 52 Week Low
- BAP $165.51
- ILMN $68.70
- 52 Week High
- BAP $280.88
- ILMN $155.99
- Technical
- Relative Strength Index (RSI)
- BAP 49.55
- ILMN 66.82
- Support Level
- BAP $254.10
- ILMN $118.50
- Resistance Level
- BAP $263.01
- ILMN $126.00
- Average True Range (ATR)
- BAP 4.67
- ILMN 5.02
- MACD
- BAP 0.25
- ILMN 2.48
- Stochastic Oscillator
- BAP 57.35
- ILMN 84.61
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.